Theratechnologies inks European Egrifta deal with Ferrer
This article was originally published in Scrip
Executive Summary
Theratechnologies has made good on its promise to look global following the November US FDA approval of Egrifta (tesamorelin for injection), used to reduce abdominal fat caused by HIV treatments. It has licensed the commercialisation rights to the product for Europe, Russia, South Korea, Taiwan and certain other central Asia countries to Ferrer.